CS Diagnostics Corporation (PK) (FZRO) ニュース

$CSDX Trending - Easy to go- on accumulation https://quotes.ino.com/charting/?s=NASDAQ_CSDX

$CSDX Tip Ranks Analysis - https://www.tipranks.com/stocks/csdx/technical-analysis

$CSDX Company Update : Not all disinfectants are created the same. While some erode surfaces over time, MEDUSA delivers powerful disinfection without degradation.

Backed by a scientifically balanced formula,
@MedusaSdp
ensures effective pathogen elimination while preserving material longevity - A smarter, safer choice for sustainable hygiene solutions.
$CSDX
https://x.com/CSDX_CSDCorp/status/1889675827627041017

$CSDX Bottom buy opportunity ? - DD - https://www.barchart.com/stocks/quotes/CSDX/cheat-sheet

$CSDX Dip buy opportunity. volume on demand get in early!!

$CSDX . is positioning itself for long-term growth with breakthrough innovations. As a listed entity on OTCQB, CS Diagnostics Corp. provides U.S. investors with access to a high-growth opportunity, ensuring long-term shareholder value by creating and executing impactful, market-leading solutions.

$CSDX Discover the future of healthcare at CS Diagnostics Corp. With our focus on improving therapy outcomes and reducing side effects, we are revolutionizing patient care on a global scale.

https://csdcorp.us/

$CSDX @MedusaSdp
comes in two powerful smart solutions;
✔️Alcohol-Based: Fast action and broad-spectrum defense. Ideal for high-traffic areas like hospitals, clinics and industrial areas.
✔️Alcohol-Free: Eco-friendly. Gentle yet highly effective for sensitive spaces, eco-conscious users, kids, pets, and food preparation areas.
Both solutions share the same purpose and redefine global hygiene standards.
$CSDX

https://x.com/CSDX_CSDCorp/status/1882782909423104404

Unlocking the potential of tomorrow’s healthcare through innovative solutions and unwavering dedication. Experience the difference with CS Diagnostics Corp, where cutting-edge technology meets compassionate care.
Learn more about the company - https://csdcorp.us/
Follow https://x.com/CSDX_CSDCorp

$CSDX CS Diagnostics Corp. serves a varied international market and specializes in traversing complicated regulatory landscapes to gain product approval and distribution. Our global presence is enhanced by strategic collaborations with healthcare sectors globally, ensuring that our comprehensive services and solutions are available in multiple countries. With a focus on quality and a strong range of solutions, CS Diagnostics Corp. is well-positioned to change the future of healthcare by delivering on our promise of greater health through better technology.

https://csdcorp.us/about-us/

$CSDX MEDUSA presents the new standard in hygiene with powerful smart disinfectant protection that is longer-lasting, safe and adapts to any environment, which means you save time and money. https://medusa-sdp.com/

$CSDX Barchart technical Analysis https://www.barchart.com/stocks/quotes/CSDX/cheat-sheet

$CSDX Company Update :
Our newest product is not just another solution; it’s a response to a growing $30B+ global market need. Engineered to provide unrivaled protection, while reducing operational costs, this innovation will entirely redefine hygiene standards.

With a multi-channel U.S. launch strategy underway, we’re gearing up for a game-changing debut! $CSDX

https://x.com/CSDX_CSDCorp/status/1879208477727285701

CSDX Nice volume today Let's see 💪

OTCMKTS: $CSDX Big Opportunity, Today BIG NEWS🔥🎯 Stay Tuned

CS Diagnostics Corp. Announces U.S. Launch of MEDUSA

$CSDX Looking toward the future, CS Diagnostics Corp. is positioning itself for long-term growth with breakthrough innovations. As a listed entity on OTCQB, CS Diagnostics Corp. provides U.S. investors with access to a high-growth opportunity, ensuring long-term shareholder value by creating and executing impactful, market-leading solutions.

$CSDX CS Diagnostics Corp. is also thrilled to be in advanced negotiations for a sponsorship deal with one of Europe’s most iconic football clubs. As a global leader in sports and entertainment, a partnership with this club would bring MEDUSA to the forefront of both the sports industry and public spaces worldwide. The market will be updated as developments unfold.

The global disinfectant market is valued at an estimated $8.37 billion in 2025, with strong demand driven by growing global health and safety concerns, particularly in a post Covid-19 world. CS Diagnostics Corp. plans to monetize MEDUSA through strategic partnerships and direct sales. By leveraging its strong network and multi-channel go-to-market strategy, the company aims to capture significant market share and drive revenue from both B2B and B2C segments.

Mohammad EsSayed, Vice President of the Board at CS Diagnostics Corp., commented:
https://aetoswire.com/en/news/cs021102025eng

$CSDX News Out! CS Diagnostics Corp. Announces U.S. Launch of MEDUSA

Innovative smart disinfectant formula suitable for a wide range of environments

In sponsorship talks with leading European football club


CS Diagnostics Corp. (OTCQB: CSDX) (or “the company”) is delighted to announce the U.S. launch of MEDUSA, alongside its product CS Protect-Hydrogel. MEDUSA is a next-generation smart disinfectant product (SDP) designed to set new hygiene standards and revolutionize hygiene practices across a variety of sectors.

MEDUSA has been approved in key global regions including the EU and the UAE and is set for U.S. approval. Significantly, this product offers full protection for up to 10 days on touched surfaces, in two formulations, which meet the diverse needs of various industries.

The core, alcohol-free formula is safe and effective for use in high-traffic environments, for example hotels, schools, public spaces, and sports venues. Additionally, an alcohol-based version is specifically formulated for medical settings such as clinics and hospitals. Backed by advanced material science, MEDUSA’s protection and efficacy make it a leading solution against pathogens. This product is designed for both B2B and B2C markets, offering businesses and individuals reliable, safe disinfecting solutions.

Thomas Fahrhoefer, President of the Board at CS Diagnostics Corp., added:

“The launch of MEDUSA in the U.S. marks a major milestone for our company. MEDUSA is the result of years of research and development, and we are confident it will play a pivotal role in improving hygiene standards across industries. We are proud to offer a solution that is not only effective, but also safe for all users, including in environments where alcohol-based disinfectants are not suitable.”

CS Diagnostics Corp. is also thrilled to be in advanced negotiations for a sponsorship deal with one of Europe’s most iconic football clubs. As a global leader in sports and entertainment, a partnership with this club would bring MEDUSA to the forefront of both the sports industry and public spaces worldwide. The market will be updated as developments unfold.

The global disinfectant market is valued at an estimated $8.37 billion in 2025, with strong demand driven by growing global health and safety concerns, particularly in a post Covid-19 world. CS Diagnostics Corp. plans to monetize MEDUSA through strategic partnerships and direct sales. By leveraging its strong network and multi-channel go-to-market strategy, the company aims to capture significant market share and drive revenue from both B2B and B2C segments.

Mohammad EsSayed, Vice President of the Board at CS Diagnostics Corp., commented:

“By launching MEDUSA, we aim to achieve $80 million in revenue in 2025, beginning with B2B sales and expanding to B2C by Q3 2025. Our projections indicate $460 million in revenue within three years. In 2025, we plan to enter five markets, with a goal of expanding to 15 markets within three years. By introducing our smart approach to preventing the spread of diseases, we aim to capture 10% of the existing disinfectant market.”

Looking toward the future, CS Diagnostics Corp. is positioning itself for long-term growth with breakthrough innovations. As a listed entity on OTCQB, CS Diagnostics Corp. provides U.S. investors with access to a high-growth opportunity, ensuring long-term shareholder value by creating and executing impactful, market-leading solutions.

Forward Looking Statements

This announcement contains forward-looking statements relating to expected or anticipated future events and anticipated results that are forward-looking in nature and, as a result, are subject to certain risks and uncertainties, such as general economic, market and business conditions, competition for qualified staff, the regulatory process and actions, technical issues, new legislation, uncertainties resulting from potential delays or changes in plans, uncertainties resulting from working in a new political jurisdiction, uncertainties regarding the results of exploration, uncertainties regarding the timing and granting of prospecting rights, uncertainties regarding the timing and granting of regulatory and other third party consents and approvals, uncertainties regarding the Company's or any third party's ability to execute and implement future plans, and the occurrence of unexpected events.

Actual results achieved may vary from the information provided herein because of numerous known and unknown risks and uncertainties and other factors.

Watch the video:

For further information please visit:

https://medusa-sdp.com/

https://csdcorp.us/


Permalink
https://aetoswire.com/en/news/cs021102025eng

Contacts
Mohammad Essayed

mohammad.essayed@csdcorp.us

https://aetoswire.com/en/news/cs021102025eng

$CSDX On watch for news

Looks like a new PR company, looks like they are getting ready for something. Finally.

https://www.otcmarkets.com/otcapi/company/dns/news/document/79204/content

FZRO changed to CSDX:
https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes

Agree.

The beauty about this stock is has only 500 thousands shares float not millions or billions. It is a real deal

This stock is worth billions of dollars. It should be at $85 by now. Drugs+medical equipments+protective equipments and it is internationally. It is made by German makers. Let’s go and lets us chatt and educate each other.

Thank you

FZRO: Heck, squeeze them THIS hard!!! (See below!!!) And then, something YOU have might get 'hard'!!!))

Congrats to you

Out

It was a great ride!!!!!!!!!!!

Amazing!

FZRO: See latest 'CHART' on this freak show, below!!!!

Damn!

In September 4, 2023 a valuation almost 1billion. https://www.otcmarkets.com/otcapi/company/financial-report/402084/content
Please read page four of 27

What are you expecting?

To what?

Are you sure it's not FZRO will hit a minimum of $600 a share of more???????

I'm going with what.......

FZRO will hit minimum $60 a share or more. It is less than 0.5 millions of public floats

Is the FDA approval knocking on the door or what?!!

Attention !

Don't squeeze them that hard LOL.

Holding tight my shares.

FZRO....ghost town 👻

Is this pump and dump done for now?

Lol 3 scolded children acting out against pappy.

Perfect example of a weak mind. Resorting to name calling. 22,000 embarrassed followers of a “top traders”.

Imo, traders selling at this level are making a mistake.

Wow! What a pump job Dinogreeves! Looks like you're against pumping on other tickers as you spew hatred toward the company and their investors who are posting their appreciation for said company while at the same time you're pumping this ticker CS Diagnostics Corp yourself! I think that's called blatant hypocrisy!...? I took a screenshot of your post too just like you said you did of mine! Here is a little song called dueling banjos: Maybe you can get the inference from it and come to the proper conclusion about your way of threatening other posters as you are!...?

Which day?

Which direction?

No publicity, just filings. I wonder how they are willing to keep this under wrap, they offices. The President owns the whole OS and control 99% of this ticker and his primary address is in Dubai. Offices Headquarters: City of Neuss in Germany: 440 sqm (monthly rent 5.000 €) City of Bruckmühl in Germany: 90 sqm (monthly rent 1.500 €). Current market cap is 110 million, price tag for the acquisition they just made 500 million dollars for Hydrogel Tech, just barely under $4.50, this President can't unload his shares here in the OTC, won't make sense, with this 500,000 float, with reasonable volume this can hit 8-10 dollars at some point, I will give it about 4-6 weeks for things to unfold, once the street discover this and looks like based on the filings they could be aiming going Nasdaq. You simply can't go wrong with a small float like this one, impeccable tech, a company that has sales and been around for 10 years, slick website that makes you go awe. Just needs more eyes on it and in-fact with the right volume this could potentially hit 20 dollars, talking about million plus volume and if this was Nasdaq it would have done that in heartbeat.
Dubai, United Arab Emirates: 50 sqm (monthly rent 1.500 €)


"The CS Protect- Hydrogel is a hydrogel-based tissue spacer. It is used in radiation therapy to increase the distance between cancer cells and healthy tissue and thus protect healthy tissue from damage caused by high doses of radiation. Currently, hydrogel spacers are used exclusively in the treatment of prostate cancer. Here, the spacer pushes the rectum away from the prostate, thus reducing rectal damage from radiation therapy. The hydrogel spacer is injected once in liquid form through a thin needle into the space between cancer cells and healthy tissue and is broken down by the body after about six months. The CS Protect-Hydrogel is a "ready-to-use" product, which is sterile packed and can be applied directly. The hydrogel can be used in radiotherapy for prostate, cervical, esophageal, bladder and breast cancer."

"On September 27, 2023, CS Diagnostics Corp, acquired 100% of the CS Protect-Hydrogel for a cost basis of Five Hundred Million USD in the form of 110,000,000 shares of CS Diagnostics Corp Common Stock. On November, 2023, CS Diagnostics Corp. filed its 3rd Quarter Report and Financial Statements with the consent of our PCAOB Auditors which represent the purchase of the CS Protect-Hydrogel. The issuer is requesting OTC Markets recognize the Issuer is no longer a shell and certainly not to be construed as a “Shell Risk”.
The issuer is now working with its partners to apply for approval of CS Protect Hydrogel with the relevant national regulatory authorities in Europe, North and South America."

“The value of the CS Diagnostics Group's right to use CS Protect-Hydrogel is mainly dependent on the market penetration and the market share achieved as well as the achievable sales prices. In the most likely scenario of a market share of 50 % and sales prices of EUR/unit 1,100 (EUR (27)) and EUR/unit 1,900 (USA), the economic benefit as the net present value of future cash surpluses as of September 30, 2023, is EUR 961 million.”